• Larimar Therapeutics posted a Q2 2026 net loss of USD 32.8 million, or USD 0.30 a share, versus a net loss of USD 26.2 million, or USD 0.41 a share, a year earlier.
• Research and development expense rose 19.86% to USD 28 million, driven by higher manufacturing work and professional fees tied to trials and BLA preparation.
• General and administrative costs climbed 43.55% to USD 6.35 million, on accelerated commercial buildout ahead of a planned mid-2027 launch, if approved.
• Cash, cash equivalents and marketable securities totaled USD 156.3 million at June 30, with cash runway projected into Q3 2027.
• Rolling BLA submission for nomlabofusp is underway with completion expected in 2H 2026; first patient dosing in a global confirmatory Phase 3 study is expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9802780) on August 04, 2026, and is solely responsible for the information contained therein.